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quality, prospective outcomes research. The methods for
establishing a network of pharmacies, recruiting patients,
and obtaining patient informed consent will be described.
The procedures for developing telephone questionnaires
and for collecting data on a broad range of topics, such as
patient demographics, drug utilization and compliance,
prescribing patterns, health services utilization, adverse
events, quality of life, out-of-pocket expenditures and
productivity losses will be discussed. Finally, the applica-
tions of community pharmacy-based outcomes research
studies will be presented. These include pharmacoeco-
nomic evaluations for formulary registration, drug utili-
zation review for improving therapeutic regimens, devel-
oping disease management strategies for optimizing care,
patient profiling for investigating utilization and compli-
ance patterns and measuring health outcomes to assess
the impact of health policy decisions. This workshop will
benefit industrial and academic researchers engaged in
prospective pharmacoeconomic assessments, health ser-
vices evaluations and outcomes research. Individuals in-
terested in outcomes research methodology and the rela-
tionship between outcomes research and health policy
decision-making may also benefit from attending.
DA4
CONSTRUCTION OF A VALIDATED,
NORMALIZED, GRANULAR ADMINISTRATIVE
DATABASE AND ITS USE IN CLINICAL
OUTCOMES IMPROVEMENT, CLINICAL
RESEARCH, AND PHARMACOECONOMIC
RESEARCH
Morris 51. Seltzer f. Bryant D'
IPremier, Inc., Charlotte, NC, USA; -Premier Research
Worldwide, Philadelphia, PA; USA
The growth in the number of studies analyzing healthcare
costs has been exponential. However, recently published
data cast doubt about their applicability. We hypothesize
that this situation may be, in part, due to the lack of
timely, validated, standardized databases. Additionally,
many of the rigorous procedures developed to assure ve-
racity of clinical research data have not been consistently
applied to the conduct of outcomes research. Similarly,
doubts about the accuracy and timeliness of administra-
tive information may hinder its application to the pro-
cesses of clinical research. We suggest that through care-
ful construction of a clinical financial database and
judicious application of clinical research tools and prac-
tices, some of these barriers may be overcome.
This workshop aims to:
1) Describe the Perspective Comparative Database
(PCD), Premier, Inc.'s standardized nationwide
ISO-center clinical financial dataset through:
• review of the methodology by which standard
data elements are defined, normalized, mapped
and validated;
• review of the methodology by which stan-
dardized costs are validated.
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2) Describe PCD's efficacy in the research arena:
• provide examples of clinical outcomes im-
provement;
• provide examples of application to clinical re-
search in the arena of patient identification and
protocol development;
• provide examples of combination with clini-
cal research tools in performance of pharmaco-
economic studies.
3) Suggest methods by which a combined PCD/clini-
cal information database might allow for rapid ac-
quisition and analysis of pharmacoeconomic data.
This workshop is intended for industry professionals
and non-industry researchers involved in applied phar-
macoeconomics, decision support systems, and clinical
research.
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DISEASE STATE MANAGEMENT TRACKER:
IMPLEMENTING, TRACKING, AND EVALUATING
CLINICAL PATHWAYS AND OUTCOMES
Ambegaonkar AJ, Day D. MainJ. Lubowski T. Yamaga C.
Van VleetJ
Clinical Pharmacy Outcomes Research, Pfizer Inc., New York,
NY, USA
Although clinical guidelines have been gaming wide-
spread acceptance as a management tool, practical diffi-
culties in implementation and measurement of outcomes
have been obstacles in their widespread use. Their com-
plexity may discourage consistent use in everyday prac-
tice, while the lack of data tracking their implementation
has limited the assessment of outcomes. Disease State
Management Tracker (DSMT) addresses these concerns
with a system that makes it easy for the practitioner to
enter patient assessments and track services received, as
well as monitor patient progress and outcomes. DSMT is
based on the components of disease state management,
namely: treatment algorithms, clinical decision making,
and outcomes reporting.
Complex treatment algorithms are easily stored and
analyzed using either retrospective or prospective data.
The DSMT software was developed as an application for
the Windows 9S/NT environment. The workshop will be
presented in the form of an overview of the DSMT and its
functionalities while using community acquired pneumo-
nia as an example disease state. The attendee will be able
to convert locally or nationally developed clinical path-
ways and enter them into the DSMT. Next, patient as-
sessment, assignment into management cells for provision
of services, and determination of patient outcomes in the
DSMT will be reviewed. Finally the capability of DSMT
to generate extensive reports will be demonstrated. Some
standard reports include determination of cost of treat-
ment via the clinical pathway as well as cost of deviations
from the pathway. DSMT is being used for various dis-
ease states including community acquired pneumonia,
asthma, osteo-arthritis, osteoporosis as well as in several
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practice environments including inpatient/out-patient
pharmacy, clinics, managed care, and LTC. The wide-
spread applicability of the DSMT will be beneficial to
healthcare practitioners, administrators, and researchers
with diverse interests from managed care organizations,
long term care, hospitals, community settings, and educa-
tional institutions.
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STRATEGIES FOR FORMULARY COMPARISONS
IN THE MEDICAID MANAGED CARE ERA
Wurtzbacher JD, Holimon TD
University of Tennessee College of Pharmacy, Memphis, TN,
USA
Traditional state Medicaid programs that adopt an open
managed care model must adapt their oversight from a
single drug formulary to multiple formularies. Following
the workshop, participants should be able to identify and
describe successful strategies for obtaining and analyzing
data needed to evaluate appropriateness of multiple drug
formularies. Practical experience with obtaining informa-
tion and creating a database containing multiple formu-
laries, procedures to incorporate analysis of drug therapy
by disease state, and different methods used to categorize
drugs for evaluation will be presented. These will be dem-
onstrated by comparing medications used for the treat-
ment of peptic ulcer disease by Medicaid managed care
formularies in the state of Tennessee. This workshop is
intended for government and healthcare industry decision
makers and others involved in quality control and im-
provement.
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PROSPECTIVE, NATURALISTIC OUTCOMES
MEASUREMENT: THE SCHIZOPHRENIA CARE
AND ASSESSMENT PROGRAM (SCAP)
Haley JCI, Russo PN, Johnstone BM', Crown WH2
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The constraints on healthcare delivery have created de-
mand for intervention analyses that address the "real
world," naturalistic setting. Retrospective databases can
provide a naturalistic view of drug and service utilization
derived from administrative data. However, there are
times when administrative data does not fully address de-
cision-makers' questions. When this is the case, prospec-
tive non-randomized studies represent another approach
that can collect more comprehensive data. This workshop
will explore the development and implementation of such
a study, the Schizophrenia Care and Assessment Program
(SCAP). SCAP evaluates the relationship between usual
medical care as delivered in various health systems and
clinical, humanistic, and economic outcomes for patients
with schizophrenia. SCAP is currently enrolling in the
United States and Australia where each patient will be
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followed for three years. The total sample will be 2,700
participants. The workshop will cover three development
stages of this project: (1) retrospective view of drug and
service utilizations patterns, (2) protocol development,
(3) site start-up and baseline characteristics of the enroll-
ees. The use pattern portion of the workshop will discuss
methods appropriate for analyses in retrospective data-
base studies. The protocol development section will dis-
cuss instrument development, instrument selection, and
administration for the setting of a naturalistic study. The
site start-up and baseline characteristics section will dis-
cuss training and enrollment issues in a study of this size
and the practical issues surrounding MIS resource use
data. Early baseline characteristics on an expected sample
of 250 U.S. enrollees will also be discussed. Attendees
will gain an understanding of design and implementation
issues in naturalistic settings for marketed products. Pro-
fessionals who expect to be involved in prospective out-
comes studies or who are interested in exploring this op-
tion should attend.
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EVALUATING HEALTH OUTCOMES AND
PHARMACOECONOMIC LITERATURE
Fulda TR, Blackburn JL
United States Pharmacopeia, Rockville, MD, USA
In 1997, the United States Pharmacopeia (USP) estab-
lished an Ad Hoc Outcomes/Cost Effectiveness Advisory
Panel to consider the development of specifications for
compiling, indexing, and evaluating outcomes research!
cost-effectiveness literature on a disease-specific basis.
Such a resource could be used to support pharmaceutical
therapy choice decision making by a variety of potential
users. The USP has developed a protype health outcomes
and pharmacoeconomic annotated registry of the litera-
ture on the disease state, congestive heart failure. Other
organizations have established and are marketing phar-
macoeconomic and health outcome literature registries,
with two examples being the HEED database (OHE-IF-
PMA Database Ltd.) and the University of York NHS
Centre for Reviews and Dissemination (DARE).
OBJECTIVE: To share experiences and to identify the
needs of decision makers for outcome/pharrnacoeco-
nomic information and to discuss whether they are being
met by currently available literature sources. Decision
makers include health care practitioners, managed care
organizations, third party payers, industry and govern-
ments.
WORKSHOP FORMAT: The USP congestive heart fail-
ure protype literature registry will be described and com-
pared to currently available pharmacoeconomic/outcome
databases. Participants will share their assessment of the
currently available abstracting service/databases and de-
termine if there is a role for further developments.
DESIRED OUTCOME: To determine if there is a need
for a collaborative approach among interested parties to
make relevant health outcome/pharmacoeconomic infor-
